Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07308886) titled 'Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)' on Dec. 24, 2025.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: National Cancer Institute (NCI)
Condition:
Kaposi Sarcoma
Intervention:
Drug: CYT107
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: January 6, 2026
Target Sample Size: 55
Countries of Recruitment:
United States
To know more, visi...